Clinical Trial ProgressManagement confirmed that recruitment for the X-TOLE2 trial will be completed in the next several months, indicating progress in the trial process.
Financial StabilityThe company ended the quarter with $691M in cash, which is believed to fund operations into 2027.
Potential Market ImpactAzetukalner has the potential to become a mainstay in the treatment of focal onset seizures, demonstrated by roughly one in three patients achieving seizure freedom for a year or longer in the ongoing X-TOLE OLE study.